Summary:
In 731 adults ≥40 years with HFpEF (LVEF ≥50%), obesity (BMI ≥30), mean BMI 38, 54% female, ±T2D, tirzepatide titrated to max 15 mg weekly over 20 weeks for median 104 weeks follow-up reduced CV death or worsening HF by 38% (HR 0.62, P=0.026), HF events by 46% (HR 0.54), improved KCCQ-CSS by 6.9 points, and reduced weight by 13.9% vs 2.2% compared to matching placebo with usual HF therapy, with higher GI-related discontinuation (6.3% vs 1.4%) and CRP reduction of 38.8% vs 5.9%.
| PICO | Description |
|---|---|
| Population | 731 adults with HFpEF (LVEF ≥50%), obesity (BMI ≥30), mean age 64, ±T2D. |
| Intervention | Tirzepatide titrated to max 15 mg weekly, median 104 weeks follow-up. |
| Comparison | Matching placebo with usual HF therapy. |
| Outcome | CV death/worsening HF -38%. KCCQ +6.9. Weight -13.9%. CRP -38.8%. |
Tirzepatide for HFpEF and Obesity (SUMMIT)
RCT · HFpEF + obesity · median 104 weeks
In obesity-related HFpEF, tirzepatide cut the composite of CV death or worsening heart failure by 38% and improved symptoms, the first hard-outcome benefit shown in this phenotype.
Clinical Context
HFpEF has historically lacked disease-modifying therapies. The obesity-HFpEF phenotype involves epicardial fat, inflammation, and volume overload.
Clinical Pearls
1. First Drug to Improve Hard Outcomes in Obesity-Related HFpEF: 38% reduction in CV death or worsening HF.
2. Benefits Go Beyond Weight Loss: CRP -40% suggests anti-inflammatory effects; rapid symptom improvement.
3. Benefit Regardless of Diabetes Status: Mechanism not primarily through glucose lowering.
4. Quality of Life Improvements Substantial: KCCQ +6.9 exceeds 5-point clinically meaningful threshold.
Practical Application
Consider tirzepatide for HFpEF + obesity (BMI ≥30). Target max tolerated dose. Monitor for diuretic dose reduction needs.
Study Limitations
Excluded BMI <30. Mortality conclusions tentative. GI discontinuation 6.3%. Long-term durability unknown.
Bottom Line
Tirzepatide reduces CV death/worsening HF by 38% in obesity-HFpEF, establishing first hard-outcome benefit in this population.
Source: Packer M, et al. “Tirzepatide for HFpEF and Obesity (SUMMIT).” NEJM, 2024. Read article